Schizophrenia Treatment Adherence Investigation (STAI)

NCT01001481 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 550

Last updated 2014-04-09

No results posted yet for this study

Summary

The primary objective of this treatment review and feedback program is to quantify the risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia.

Conditions

Interventions

OTHER

Risk status for medication adherence

Examination of risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia

Sponsors & Collaborators

  • Janssen-Cilag Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag Pty Ltd Clinical Trial · Janssen-Cilag Pty Ltd

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2009-09-30
Completion
2009-09-30

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01001481 on ClinicalTrials.gov